To test, whether the specific vulnerability of NRAS-mutant cancer cells to NRAS inhibition expands beyond melanoma, we tested if the treatment may impact cell-growth in NRAS-mutant multiple myeloma (MM, H929) and small cell lung cancer (SCLC, SW1271) cells. This evidence concerns the gene NRAS and plasma cell myeloma.